43
Participants
Start Date
January 21, 2021
Primary Completion Date
March 8, 2024
Study Completion Date
August 31, 2025
futibatinib and pembrolizumab (KEYTRUDA®))
Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
Hospital de La Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall d'Hebrón, Barcelona
ALTHAIA, Xarxa Assistencial Universitària de Manresa, Manresa
Institut Paoli Calmettes - Hôpital de jour, Marseille
Hospital Universitario Reina Sofia, Córdoba
Centre Georges-François Leclerc, Dijon
Hospital Universitario HMN Sanchinarro, Madrid
Hospital Universitario Marqués de Valdecilla, Santander
Hospital la Fe, Valencia
Henry Ford Hospital, Detroit
Centre Regional de Lutte Contre le Cancer de Lorraine, Vandœuvre-lès-Nancy
ICANS - Institut de cancérologie de Strasbourg Europe, Strasbourg
Centre Leon Berard - departement d'oncologie medicale, Lyon
Comprehensive Care Centers of Nevada, Las Vegas
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Institut De Cancerologie Gustave Roussy, Villejuif
Dana Farber Cancer Institute, Boston
Hospital Clinic de Barcelona, Barcelona
Merck Sharp & Dohme LLC
INDUSTRY
Taiho Oncology, Inc.
INDUSTRY